APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tumour Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Tumour Vaccine Market Outlook and Growth Opportunities 2026

31 December 2025207 pages

Choose your research edition.

Industry ResearchTumour Vaccine Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumour Vaccine Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Tumour Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumour Vaccine Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumour Vaccine Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Tumour Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Tumour Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tumour Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tumour Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Tumour Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Tumour Vaccine market include Advaxis, Agenus Inc, Avidea Technologies, BioNTech, BrightPath Biotherapeutics, Genocea Biosciences Inc, Gritstone Bio, ISA Pharmaceuticals and Medigene AG, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Tumour Vaccine market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tumour Vaccine and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tumour Vaccine revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Tumour Vaccine market.

Tumour Vaccine Segment by Company

Advaxis

Agenus Inc

Avidea Technologies

BioNTech

BrightPath Biotherapeutics

Genocea Biosciences Inc

Gritstone Bio

ISA Pharmaceuticals

Medigene AG

Moderna

Nouscom

Novogene

OSE Immunotherapeutics

Roche Holding AG

Vaccibody AS

Vaximm AG

ZIOPHARM Oncology

Pfizer

Eli Lilly and Company

Merck & Co Inc

Tumour Vaccine Segment by Type

Personalized Vaccine

Off-the shelf Vaccine

Tumour Vaccine Segment by Application

Gastrointestinal Cancer

Lung Cancer

Melanoma Cancer

Brain Cancer

Others

Tumour Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Tumour Vaccine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Tumour Vaccine key companies, revenue, market share, and recent developments.

3. To split the Tumour Vaccine breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Tumour Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Tumour Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Tumour Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumour Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumour Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumour Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tumour Vaccine industry.

Chapter 3: Detailed analysis of Tumour Vaccine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Tumour Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Tumour Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Tumour Vaccine Industry Trends Table 2. Tumour Vaccine Industry Drivers Table 3. Tumour Vaccine Industry Opportunities and Challenges Table 4. Tumour Vaccine Industry Restraints Table 5. Global Tumour Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Tumour Vaccine Revenue Share by Company (2021-2026) Table 7. Global Tumour Vaccine Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Tumour Vaccine Key Company Manufacturing Base & Headquarters Table 9. Global Tumour Vaccine Company, Product Type & Application Table 10. Global Tumour Vaccine Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Tumour Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Personalized Vaccine Table 15. Significant Companies of Off-the shelf Vaccine Table 16. Global Tumour Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Tumour Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Tumour Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Tumour Vaccine Sales Value Share by Type (2021-2026) Table 20. Global Tumour Vaccine Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Gastrointestinal Cancer Table 22. Significant Companies of Lung Cancer Table 23. Significant Companies of Melanoma Cancer Table 24. Significant Companies of Brain Cancer Table 25. Significant Companies of Others Table 26. Global Tumour Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Tumour Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Tumour Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Tumour Vaccine Sales Value Share by Application (2021-2026) Table 30. Global Tumour Vaccine Sales Value Share by Application (2027-2032) Table 31. Global Tumour Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Tumour Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Tumour Vaccine Sales Value Share by Region (2021-2026) Table 34. Global Tumour Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Tumour Vaccine Sales Value Share by Region (2027-2032) Table 36. Global Tumour Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Tumour Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Tumour Vaccine Sales Value Market Share by Country (2021-2026) Table 39. Global Tumour Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Tumour Vaccine Sales Value Market Share by Country (2027-2032) Table 41. Advaxis Company Information Table 42. Advaxis Business Overview Table 43. Advaxis Tumour Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Advaxis Tumour Vaccine Product Portfolio Table 45. Advaxis Recent Development Table 46. Agenus Inc Company Information Table 47. Agenus Inc Business Overview Table 48. Agenus Inc Tumour Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Agenus Inc Tumour Vaccine Product Portfolio Table 50. Agenus Inc Recent Development Table 51. Avidea Technologies Company Information Table 52. Avidea Technologies Business Overview Table 53. Avidea Technologies Tumour Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Avidea Technologies Tumour Vaccine Product Portfolio Table 55. Avidea Technologies Recent Development Table 56. BioNTech Company Information Table 57. BioNTech Business Overview Table 58. BioNTech Tumour Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. BioNTech Tumour Vaccine Product Portfolio Table 60. BioNTech Recent Development Table 61. BrightPath Biotherapeutics Company Information Table 62. BrightPath Biotherapeutics Business Overview Table 63. BrightPath Biotherapeutics Tumour Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. BrightPath Biotherapeutics Tumour Vaccine Product Portfolio Table 65. BrightPath Biotherapeutics Recent Development Table 66. Genocea Biosciences Inc Company Information Table 67. Genocea Biosciences Inc Business Overview Table 68. Genocea Biosciences Inc Tumour Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Genocea Biosciences Inc Tumour Vaccine Product Portfolio Table 70. Genocea Biosciences Inc Recent Development Table 71. Gritstone Bio Company Information Table 72. Gritstone Bio Business Overview Table 73. Gritstone Bio Tumour Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Gritstone Bio Tumour Vaccine Product Portfolio Table 75. Gritstone Bio Recent Development Table 76. ISA Pharmaceuticals Company Information Table 77. ISA Pharmaceuticals Business Overview Table 78. ISA Pharmaceuticals Tumour Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. ISA Pharmaceuticals Tumour Vaccine Product Portfolio Table 80. ISA Pharmaceuticals Recent Development Table 81. Medigene AG Company Information Table 82. Medigene AG Business Overview Table 83. Medigene AG Tumour Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Medigene AG Tumour Vaccine Product Portfolio Table 85. Medigene AG Recent Development Table 86. Moderna Company Information Table 87. Moderna Business Overview Table 88. Moderna Tumour Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Moderna Tumour Vaccine Product Portfolio Table 90. Moderna Recent Development Table 91. Nouscom Company Information Table 92. Nouscom Business Overview Table 93. Nouscom Tumour Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Nouscom Tumour Vaccine Product Portfolio Table 95. Nouscom Recent Development Table 96. Novogene Company Information Table 97. Novogene Business Overview Table 98. Novogene Tumour Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Novogene Tumour Vaccine Product Portfolio Table 100. Novogene Recent Development Table 101. OSE Immunotherapeutics Company Information Table 102. OSE Immunotherapeutics Business Overview Table 103. OSE Immunotherapeutics Tumour Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. OSE Immunotherapeutics Tumour Vaccine Product Portfolio Table 105. OSE Immunotherapeutics Recent Development Table 106. Roche Holding AG Company Information Table 107. Roche Holding AG Business Overview Table 108. Roche Holding AG Tumour Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Roche Holding AG Tumour Vaccine Product Portfolio Table 110. Roche Holding AG Recent Development Table 111. Vaccibody AS Company Information Table 112. Vaccibody AS Business Overview Table 113. Vaccibody AS Tumour Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Vaccibody AS Tumour Vaccine Product Portfolio Table 115. Vaccibody AS Recent Development Table 116. Vaximm AG Company Information Table 117. Vaximm AG Business Overview Table 118. Vaximm AG Tumour Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Vaximm AG Tumour Vaccine Product Portfolio Table 120. Vaximm AG Recent Development Table 121. ZIOPHARM Oncology Company Information Table 122. ZIOPHARM Oncology Business Overview Table 123. ZIOPHARM Oncology Tumour Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. ZIOPHARM Oncology Tumour Vaccine Product Portfolio Table 125. ZIOPHARM Oncology Recent Development Table 126. Pfizer Company Information Table 127. Pfizer Business Overview Table 128. Pfizer Tumour Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Pfizer Tumour Vaccine Product Portfolio Table 130. Pfizer Recent Development Table 131. Eli Lilly and Company Company Information Table 132. Eli Lilly and Company Business Overview Table 133. Eli Lilly and Company Tumour Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Eli Lilly and Company Tumour Vaccine Product Portfolio Table 135. Eli Lilly and Company Recent Development Table 136. Merck & Co Inc Company Information Table 137. Merck & Co Inc Business Overview Table 138. Merck & Co Inc Tumour Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Merck & Co Inc Tumour Vaccine Product Portfolio Table 140. Merck & Co Inc Recent Development Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Tumour Vaccine Product Image Figure 2. Global Tumour Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tumour Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Tumour Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Personalized Vaccine Image Figure 8. Off-the shelf Vaccine Image Figure 9. Global Tumour Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Tumour Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Tumour Vaccine Sales Value Share by Type (2021-2032) Figure 12. Gastrointestinal Cancer Image Figure 13. Lung Cancer Image Figure 14. Melanoma Cancer Image Figure 15. Brain Cancer Image Figure 16. Others Image Figure 17. Global Tumour Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Tumour Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Tumour Vaccine Sales Value Share by Application (2021-2032) Figure 20. Global Tumour Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Tumour Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Tumour Vaccine Sales Value (2021-2032) & (US$ Million) Figure 23. North America Tumour Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Tumour Vaccine Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Tumour Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Tumour Vaccine Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Tumour Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Tumour Vaccine Sales Value (2021-2032) & (US$ Million) Figure 29. South America Tumour Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Tumour Vaccine Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Tumour Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Tumour Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Tumour Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Tumour Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Personalized Vaccine
  • Off-the shelf Vaccine
Applications
  • Gastrointestinal Cancer
  • Lung Cancer
  • Melanoma Cancer
  • Brain Cancer
  • Others
Companies covered
  • Advaxis
  • Agenus Inc
  • Avidea Technologies
  • BioNTech
  • BrightPath Biotherapeutics
  • Genocea Biosciences Inc
  • Gritstone Bio
  • ISA Pharmaceuticals
  • Medigene AG
  • Moderna
  • Nouscom
  • Novogene
  • OSE Immunotherapeutics
  • Roche Holding AG
  • Vaccibody AS
  • Vaximm AG
  • ZIOPHARM Oncology
  • Pfizer
  • Eli Lilly and Company
  • Merck & Co Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Tumour Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Tumour Vaccine Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Tumour Vaccine Market Dynamics
  1. 2.1 Tumour Vaccine Industry Trends
  2. 2.2 Tumour Vaccine Industry Drivers
  3. 2.3 Tumour Vaccine Industry Opportunities and Challenges
  4. 2.4 Tumour Vaccine Industry Restraints
3 Tumour Vaccine Market by Company
  1. 3.1 Global Tumour Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Tumour Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Tumour Vaccine Company Ranking (2024-2026)
  4. 3.4 Global Tumour Vaccine Company Manufacturing Base and Headquarters
  5. 3.5 Global Tumour Vaccine Company Product Type and Application
  6. 3.6 Global Tumour Vaccine Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Tumour Vaccine Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Tumour Vaccine Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Tumour Vaccine Market by Type
  1. 4.1 Tumour Vaccine Type Introduction
  2. 4.1.1 Personalized Vaccine
  3. 4.1.2 Off-the shelf Vaccine
  4. 4.2 Global Tumour Vaccine Sales Value by Type
  5. 4.2.1 Global Tumour Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Tumour Vaccine Sales Value by Type (2021-2032)
  7. 4.2.3 Global Tumour Vaccine Sales Value Share by Type (2021-2032)
5 Tumour Vaccine Market by Application
  1. 5.1 Tumour Vaccine Application Introduction
  2. 5.1.1 Gastrointestinal Cancer
  3. 5.1.2 Lung Cancer
  4. 5.1.3 Melanoma Cancer
  5. 5.1.4 Brain Cancer
  6. 5.1.5 Others
  7. 5.2 Global Tumour Vaccine Sales Value by Application
  8. 5.2.1 Global Tumour Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Tumour Vaccine Sales Value by Application (2021-2032)
  10. 5.2.3 Global Tumour Vaccine Sales Value Share by Application (2021-2032)
6 Tumour Vaccine Regional Value Analysis
  1. 6.1 Global Tumour Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tumour Vaccine Sales Value by Region (2021-2032)
  3. 6.2.1 Global Tumour Vaccine Sales Value by Region: 2021-2026
  4. 6.2.2 Global Tumour Vaccine Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Tumour Vaccine Sales Value (2021-2032)
  7. 6.3.2 North America Tumour Vaccine Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Tumour Vaccine Sales Value (2021-2032)
  10. 6.4.2 Europe Tumour Vaccine Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Tumour Vaccine Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Tumour Vaccine Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Tumour Vaccine Sales Value (2021-2032)
  16. 6.6.2 South America Tumour Vaccine Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Tumour Vaccine Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Tumour Vaccine Sales Value Share by Country, 2025 VS 2032
7 Tumour Vaccine Country-level Value Analysis
  1. 7.1 Global Tumour Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Tumour Vaccine Sales Value by Country (2021-2032)
  3. 7.2.1 Global Tumour Vaccine Sales Value by Country (2021-2026)
  4. 7.2.2 Global Tumour Vaccine Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Tumour Vaccine Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Tumour Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Tumour Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Tumour Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Tumour Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Tumour Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Tumour Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Tumour Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Tumour Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Tumour Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Tumour Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Tumour Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Tumour Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Tumour Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Tumour Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Tumour Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Tumour Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Tumour Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Tumour Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Tumour Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Tumour Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Tumour Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Tumour Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Tumour Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Tumour Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Tumour Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Tumour Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Tumour Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Tumour Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Tumour Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Advaxis
  2. 8.1.1 Advaxis Company Information
  3. 8.1.2 Advaxis Business Overview
  4. 8.1.3 Advaxis Tumour Vaccine Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Advaxis Tumour Vaccine Product Portfolio
  6. 8.1.5 Advaxis Recent Developments
  7. 8.2 Agenus Inc
  8. 8.2.1 Agenus Inc Company Information
  9. 8.2.2 Agenus Inc Business Overview
  10. 8.2.3 Agenus Inc Tumour Vaccine Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Agenus Inc Tumour Vaccine Product Portfolio
  12. 8.2.5 Agenus Inc Recent Developments
  13. 8.3 Avidea Technologies
  14. 8.3.1 Avidea Technologies Company Information
  15. 8.3.2 Avidea Technologies Business Overview
  16. 8.3.3 Avidea Technologies Tumour Vaccine Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Avidea Technologies Tumour Vaccine Product Portfolio
  18. 8.3.5 Avidea Technologies Recent Developments
  19. 8.4 BioNTech
  20. 8.4.1 BioNTech Company Information
  21. 8.4.2 BioNTech Business Overview
  22. 8.4.3 BioNTech Tumour Vaccine Revenue and Gross Margin (2021-2026)
  23. 8.4.4 BioNTech Tumour Vaccine Product Portfolio
  24. 8.4.5 BioNTech Recent Developments
  25. 8.5 BrightPath Biotherapeutics
  26. 8.5.1 BrightPath Biotherapeutics Company Information
  27. 8.5.2 BrightPath Biotherapeutics Business Overview
  28. 8.5.3 BrightPath Biotherapeutics Tumour Vaccine Revenue and Gross Margin (2021-2026)
  29. 8.5.4 BrightPath Biotherapeutics Tumour Vaccine Product Portfolio
  30. 8.5.5 BrightPath Biotherapeutics Recent Developments
  31. 8.6 Genocea Biosciences Inc
  32. 8.6.1 Genocea Biosciences Inc Company Information
  33. 8.6.2 Genocea Biosciences Inc Business Overview
  34. 8.6.3 Genocea Biosciences Inc Tumour Vaccine Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Genocea Biosciences Inc Tumour Vaccine Product Portfolio
  36. 8.6.5 Genocea Biosciences Inc Recent Developments
  37. 8.7 Gritstone Bio
  38. 8.7.1 Gritstone Bio Company Information
  39. 8.7.2 Gritstone Bio Business Overview
  40. 8.7.3 Gritstone Bio Tumour Vaccine Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Gritstone Bio Tumour Vaccine Product Portfolio
  42. 8.7.5 Gritstone Bio Recent Developments
  43. 8.8 ISA Pharmaceuticals
  44. 8.8.1 ISA Pharmaceuticals Company Information
  45. 8.8.2 ISA Pharmaceuticals Business Overview
  46. 8.8.3 ISA Pharmaceuticals Tumour Vaccine Revenue and Gross Margin (2021-2026)
  47. 8.8.4 ISA Pharmaceuticals Tumour Vaccine Product Portfolio
  48. 8.8.5 ISA Pharmaceuticals Recent Developments
  49. 8.9 Medigene AG
  50. 8.9.1 Medigene AG Company Information
  51. 8.9.2 Medigene AG Business Overview
  52. 8.9.3 Medigene AG Tumour Vaccine Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Medigene AG Tumour Vaccine Product Portfolio
  54. 8.9.5 Medigene AG Recent Developments
  55. 8.10 Moderna
  56. 8.10.1 Moderna Company Information
  57. 8.10.2 Moderna Business Overview
  58. 8.10.3 Moderna Tumour Vaccine Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Moderna Tumour Vaccine Product Portfolio
  60. 8.10.5 Moderna Recent Developments
  61. 8.11 Nouscom
  62. 8.11.1 Nouscom Company Information
  63. 8.11.2 Nouscom Business Overview
  64. 8.11.3 Nouscom Tumour Vaccine Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Nouscom Tumour Vaccine Product Portfolio
  66. 8.11.5 Nouscom Recent Developments
  67. 8.12 Novogene
  68. 8.12.1 Novogene Company Information
  69. 8.12.2 Novogene Business Overview
  70. 8.12.3 Novogene Tumour Vaccine Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Novogene Tumour Vaccine Product Portfolio
  72. 8.12.5 Novogene Recent Developments
  73. 8.13 OSE Immunotherapeutics
  74. 8.13.1 OSE Immunotherapeutics Company Information
  75. 8.13.2 OSE Immunotherapeutics Business Overview
  76. 8.13.3 OSE Immunotherapeutics Tumour Vaccine Revenue and Gross Margin (2021-2026)
  77. 8.13.4 OSE Immunotherapeutics Tumour Vaccine Product Portfolio
  78. 8.13.5 OSE Immunotherapeutics Recent Developments
  79. 8.14 Roche Holding AG
  80. 8.14.1 Roche Holding AG Company Information
  81. 8.14.2 Roche Holding AG Business Overview
  82. 8.14.3 Roche Holding AG Tumour Vaccine Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Roche Holding AG Tumour Vaccine Product Portfolio
  84. 8.14.5 Roche Holding AG Recent Developments
  85. 8.15 Vaccibody AS
  86. 8.15.1 Vaccibody AS Company Information
  87. 8.15.2 Vaccibody AS Business Overview
  88. 8.15.3 Vaccibody AS Tumour Vaccine Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Vaccibody AS Tumour Vaccine Product Portfolio
  90. 8.15.5 Vaccibody AS Recent Developments
  91. 8.16 Vaximm AG
  92. 8.16.1 Vaximm AG Company Information
  93. 8.16.2 Vaximm AG Business Overview
  94. 8.16.3 Vaximm AG Tumour Vaccine Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Vaximm AG Tumour Vaccine Product Portfolio
  96. 8.16.5 Vaximm AG Recent Developments
  97. 8.17 ZIOPHARM Oncology
  98. 8.17.1 ZIOPHARM Oncology Company Information
  99. 8.17.2 ZIOPHARM Oncology Business Overview
  100. 8.17.3 ZIOPHARM Oncology Tumour Vaccine Revenue and Gross Margin (2021-2026)
  101. 8.17.4 ZIOPHARM Oncology Tumour Vaccine Product Portfolio
  102. 8.17.5 ZIOPHARM Oncology Recent Developments
  103. 8.18 Pfizer
  104. 8.18.1 Pfizer Company Information
  105. 8.18.2 Pfizer Business Overview
  106. 8.18.3 Pfizer Tumour Vaccine Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Pfizer Tumour Vaccine Product Portfolio
  108. 8.18.5 Pfizer Recent Developments
  109. 8.19 Eli Lilly and Company
  110. 8.19.1 Eli Lilly and Company Company Information
  111. 8.19.2 Eli Lilly and Company Business Overview
  112. 8.19.3 Eli Lilly and Company Tumour Vaccine Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Eli Lilly and Company Tumour Vaccine Product Portfolio
  114. 8.19.5 Eli Lilly and Company Recent Developments
  115. 8.20 Merck & Co Inc
  116. 8.20.1 Merck & Co Inc Company Information
  117. 8.20.2 Merck & Co Inc Business Overview
  118. 8.20.3 Merck & Co Inc Tumour Vaccine Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Merck & Co Inc Tumour Vaccine Product Portfolio
  120. 8.20.5 Merck & Co Inc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst